SHZ · 002349.SZ
Jinghua Pharmaceutical Group Co., Ltd.
CN¥6.91+CN¥0.13 (+1.92%)
Jinghua Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.95% below the high.
Loading market information…
SHH · 688176.SS · CNY
Stock price, earnings
Quote as of Oct 30, 2026, 06:15 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jiangsu Yahong Meditech Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 38.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jiangsu Yahong Meditech Co Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥6.91+CN¥0.13 (+1.92%)
Jinghua Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.95% below the high.
CN¥5.45+CN¥0.01 (+0.18%)
Blue Sail Medical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 38.83% below the high.
CN¥8.75+CN¥0.20 (+2.34%)
Teyi Pharmaceutical Group Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
CN¥19.46-CN¥0.34 (-1.72%)
Shenzhen Weiguang Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.41% below the high.
CN¥10.04+CN¥0.27 (+2.76%)
Hunan Fangsheng Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.63% below the high.
CN¥3.99+CN¥0.00 (0.0%)
Luoxin Pharmaceuticals Group Stock Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.44% below the high.
CN¥3.58+CN¥0.03 (+0.85%)
Fuan Pharmaceutical (Group) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.4% below the high.
CN¥26.74+CN¥0.48 (+1.83%)
Jianmin Pharmaceutical Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.65% below the high.
